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Abstract: MicroRNAs (miRNAs) regulate gene expression at posttranscriptional level by triggering
RNA interference. In such a sense, aberrant expressions of miRNAs play critical roles in the
pathogenesis of many disorders, including Parkinson’s disease (PD). Controlling the level of specific
miRNAs in the brain is thus a promising therapeutic strategy for neuroprotection. A fundamental
need for miRNA regulation (either replacing or inhibition) is a carrier capable of delivering
oligonucleotides into brain cells. This study aimed to examine a polymeric magnetic particle,
Neuromag®, for delivery of synthetic miRNA inhibitors in the rat central nervous system. We injected
the miRNA inhibitor complexed with Neuromag® into the lateral ventricles next to the striatum,
by stereotaxic surgery. Neuromag efficiently delivered oligonucleotides in the striatum and
septum areas, as shown by microscopy imaging of fluorescein isothiocyanate (FITC)-labeled oligos
in astrocytes and neurons. Transfected oligos showed efficacy concerning miRNA inhibition.
Neuromag®-structured miR-134 antimiR (0.36 nmol) caused a significant 0.35 fold decrease of striatal
miR-134, as revealed by real-time quantitative polymerase chain reaction (RT-qPCR). In conclusion,
the polymeric magnetic particle Neuromag® efficiently delivered functional miRNA inhibitors in
brain regions surrounding lateral ventricles, particularly the striatum. This delivery system holds
potential as a promising miRNA-based disease-modifying drug and merits further pre-clinical studies
using animal models of PD.
Keywords: miRNA; nanoparticles; Neuromag®; delivery
1. Introduction
MicroRNAs (miRNAs) are endogenous short noncoding RNAs that cause post-transcriptional
gene silencing in healthy cells. Knocking down first requires the binding of miRNA guide strands,
complexed with silencing proteins, to complementary sequences in 30-untranslated region (30-UTR)
of the target mRNAs. This silencing complex will ultimately cause translational repression or
mRNA degradation [1]. RNAi is thus a crucial mechanism of gene regulation. Conversely,
aberrant expressions of miRNAs play critical roles in the neuropathology of brain diseases [2].
Therefore, exogenous synthetic oligonucleotides have been used to modulate the content of specific
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miRNAs. Antisense single-stranded oligos (AntimiRs) are capable of annealing to the guide strand of
mature miRNAs, forming hetero-duplexes devoided of RNAi activity [1,3].
Regarding brain diseases, AntimiRs were first used to suppress the overexpression of miR-134 in
brain areas related to cell death and epileptogenesis [4]. A seminal work of Henshall0s group reported
the efficacy of AntimiR-134 injected by the intracerebroventricular (i.c.v.) route in reducing the loss of
hippocampal cells and the number of seizures in the model of epilepsy triggered by intra-amygdalar
injection of kainic acid [5]. The neuroprotective effects of brain-injected miR-134-targeted AntimiRs
were corroborated in other models of temporal lobe epilepsy, including pilocarpine, pentylenetetrazol,
and perforant pathway stimulation [6,7]. Indeed, our group found that AntimiRs also attenuated the
injury of dopaminergic SH-SY5Y cells triggered by rotenone, a cellular model of Parkinson’s disease
(PD) [8]. Therefore, an i.c.v. injection of AntimiRs might protect neurons in the rat striatum, a region
critically involved in PD neuropathology.
Although many synthetic oligonucleotides have shown clinical efficacy in a broad range of
pathologies, transfection of neuronal cells for treating brain diseases remains a prominent challenge [9].
The blood-brain barrier and the complex cellular organization in the brain make the central nervous
system (CNS) a pharmacological biophase relatively difficult to reach. In such sense, viral vectors
remain predominantly used in clinical trials due to their higher transfecting efficiency [10]. However,
these platforms hold disadvantages such as induction of inflammatory responses and potential
mutagenic effects in the host [11,12]. Non-viral vectors, in contrast, present lower immunogenicity
and higher nucleic acid packing capacity [13]. Additionally, non-viral formulations can be produced
on a large scale with high reproducibility and acceptable costs, with relative stability for storage [14].
In this context, the magnetofection technology has employed advanced functional nanocarriers with
an increased transfection rate in neurons. The principle of this technology consists of a magnetic
nanoparticle set up with magnetic fields that will drive gene delivery [15]. These particles contain
biocompatible materials with a magnetic core and are capable of carrying nucleic acid molecules,
such as DNA plasmids, oligonucleotides, siRNAs, and miRNAs [16,17]. The principal advantage
of such a delivery system is that the endocytotic uptake mechanism—the transfection—is markedly
enhanced by magnetic fields, thus the nomination “magnetofection” [15].
Our group described for the first time the capacity of NeuroMag®—the magnetic particle
employed in the present study, to deliver nucleic acids in vivo into rat brain cells [18]. This polymeric
carrier took advantage of magnetic fields and delivered plasmids selectively into neuronal cells of
the rat visual cortex. No previous work, however, has yet tested whether NeuroMag® displays an
ability to transfect cells with functional short antisense oligonucleotides for miRNA inhibition. In the
present study, we examined whether NeuroMag®-complexed miR-134 inhibitors injected by the i.c.v.
route would efficiently knock-down miR-134 in the rat striatum, a brain region directly involved in
Parkinson0s disease neuropathology (Scheme 1).
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Scheme 1. Schematic view of magnetofection for delivering oligonucleotides in the rat brain, based 
on previous work [18]. Neuromag®-complexed oligos were injected by stereotaxic surgery in the right 
lateral ventricle, in coordinates according to the Paxinos atlas. A magnetic plate placed underneath 
the head enhances transfection of magnetic particles into the neuron and glial cells. Detailed 
information in material and methods section (item 4.1). CPu—caudate putamen; LV—lateral 
ventricle. 
2. Results 
2.1. Magnetoparticle Characterization 
The Neuromag® magnetic nanoparticles and the magnetoplexes Neuromag®-complexed oligos 
were determined in terms of size, polydispersity index (PDI) and zeta potential. The pure magnetic 
nanoparticles’ average diameter was 188.84 nm with a polydispersity index of 0.25 and a superficial 
positive charge of + 52.04 mV. After conjugation with the anti-miRNA to form magnetoplexes, the 
average diameter increased to 205.55 nm with a polydispersity index of 0.29 and the superficial 
charge decreased to −34.39 mV. 
2.2. Transfection of Fluorescein Isothiocyanate (FITC)-Labeled Oligos in the Rat Striatum Cells by Using 
Neuromag£ and Magnetic Fields 
This work then examined whether the intracerebroventricular (i.c.v.) route of administration 
would allow Neuromag®-complexed oligonucleotides to reach the striatum, a brain area strikingly 
relevant for PD. For that, we employed fluorescent fluorescein isothiocyanate (FITC)-labeled oligos 
i.c.v. injected and carried out microscope imaging. Magnetofection with Neuromag® enhanced by 
magnetic plates was effective in driving the oligos across the ependymal cell layer adjacent to the 
right striatum, and for the subsequent delivery in striatal cells (Figure 1b). Green fluorescent FITC-
labeled oligos were next to the cell nucleus of striatal neurons stained by NeuN, and also in GFAP-
positive glial cells (Figure 1c, upper and bottom, respectively). As shown in Figure 1a, the 
contralateral noninjected hemisphere showed no FITC-oligonucleotide green fluorescence. This work 
proceeded to additional brain injections into the rat visual cortex, for comparison with the first in 
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head enhances transfectio of magnetic p rticles into the neur n and glial cells. Detailed informa ion
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2. Results
2.1. Magnetoparticle Characterization
The Neuromag® magnetic nanoparticles and the magnetoplexes Neuromag®-complexed oligos
were determined in terms of size, polydispersity index (PDI) and zeta potential. The pure magnetic
nanoparticles’ average diameter was 188.84 nm with a polydispersity index of 0.25 and a superficial
positive charge of +52.04 mV. After conjugation with the anti-miRNA to form magnetoplexes,
the average diameter increased to 205.55 nm with a polydispersity index of 0.29 and the superficial
charge decreased to  34.39 mV.
2.2. Transfection of Fluorescein Isothiocyanate (FITC)-Labeled Oligos in the Rat Striatum Cells by Using
Neuromag® and Magnetic Fields
This work then examine whether the intracerebroventricular (i.c.v.) route of administration
would allow Neuromag®-complexed oligonucleotides to reach the striatum, a brain area strikingly
relevant for PD. For that, we employed fluorescent fluorescein isothiocyanate (FITC)-labeled oligos
i.c.v. injected and carried out microscope imaging. Magnetofection with Neuromag® enhanced by
magnetic plates was effective in driving the oligos across the ependymal cell layer adjacent to the right
striatum, and for the subsequent delivery in striatal cells (Figure 1b). Green fluorescent FITC-labeled
oligos were next to the cell nucleus of striatal neurons stained by NeuN, and also in GFAP-positive glial
cells (Figure 1c, upper and bottom, respectively). As shown in Figure 1a, the contralateral noninjected
hemisphere showed no FITC-oligonucleotide green fluorescence. This work proceeded to additional
brain injections into the rat visual cortex, for comparison with the first in vivo testing of Neuromag®
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injected in that region [18]. We also found positive fluorescence in apical dendrites and somas of the
pyramidal cells (Figure S1).
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Neuromag® for delivery into the neuron and glial cells. (a) Left rat striatum without 
intracerebroventricular (i.c.v.) injection (negative control); (b) NeuN-positive neuron cells transfected 
with green fluorescent FITC-labeled oligos; (c) Delineated region of (b) in high magnification 
revealing the green-labeled oligonucleotide inside neurons and glial cells (upper and bottom images, 
respectively). Immunostaining of NeuN and GFAP in red; FITC-labeled oligos in green; cell nucleus 
in blue, stained by the Hoescht 33342 reagent. Scale = 15 µm. n = 3 per group. 
2.3. Silencing of miR-134 by the Neuromag® -Complexed AntimiR-134 
The imaging of FITC-labeled oligos described above (Figure 1) revealed a clear biodistribution 
from the injection site in lateral ventricle to surrounding tissues including striatum, an area critically 
involved in PD dopaminergic degeneration. Thus we examined whether an i.c.v. injection of 
AntimiR-134 + Neuromag® would produce the desired effect, i.e., the knock-down on striatal miR-
134. For that, we quantified by RT-qPCR the level of miR-134 in rat striatal tissues manually dissected 
at seven days after i.c.v. injection. AntimiR-134-injected animals presented a marked reduction of 
miR-134 in the striatum, as shown in Figure 2. Injecting 0.36 nmol of AntimiR-134 complexed with 
Neuromag® caused a 0.35 fold decrease of this miRNA compared to controls, revealing an efficient 
and sustained knockdown (P < 0.05). Furthermore, injections of the nonsense scrambled miRNA 
sequences caused a small and not significant effect on miR-134 content. That means the miR-134 
knockdown triggered by AntimiR-134 was sequence-dependent and target specific, which is crucial 
for achieving a further miRNA-based neuroprotective therapy. 
Figure 1. Magnetofection of striatal cells by fluorescein isothiocyanate (FITC)-labeled oligonucleotides
complexed with Neuromag®. Striatum region transfected with oligos structured in Neuromag®
for delivery into the neuron and glial cells. (a) Left rat striatum without intracerebroventricular
(i.c.v.) injection (negative control); (b) NeuN-positive neuron cells transfected with green
fluorescent FITC-labeled oligos; (c) Delineated region of (b) in high magnification revealing the
green-labeled oligonucleotide inside neurons and glial cells (upper and bottom images, respectively).
Immunostaining of NeuN and GFAP in red; FITC-labeled oligos in green; cell nucleus in blue, stained by
the Hoescht 33342 reagent. Scale = 15 µm. n = 3 per group.
2.3. Silencing of miR-134 by the Neuromag® -Complexed AntimiR-134
The imaging of FITC-labeled oligos described above (Figure 1) revealed a clear biodistribution
from the injection site in lateral ventricle to surrounding tissues including striatum, an area critically
involved in PD dopaminergic degeneration. Thus we examined whether an i.c.v. injection of
AntimiR-134 + Neuromag® would produce the desired effect, i.e., the knock-down on striatal miR-134.
For that, we quantified by RT-qPCR the level of miR-134 in rat striatal tissues manually dissected
at seven days after i.c.v. injection. AntimiR-134-injected animals presented a marked reduction of
miR-134 in the striatum, as shown in Figure 2. Injecting 0.36 nmol of AntimiR-134 complexed with
Neuromag® caused a 0.35 fold decrease of this miRNA compared to controls, revealing an efficient and
sustained knockdown (P < 0.05). Furthermore, injections of the nonsense scrambled miRNA sequences
caused a small and not significant effect on miR-134 content. That means the miR-134 knockdown
triggered by AntimiR-134 was sequence-dependent and target specific, which is crucial for achieving a
further miRNA-based neuroprotective therapy.
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Figure 2. Knocking down on striatal miR-134 by Neuromag-complexed AntimiR-134 oligos. The 
content of miR-134 in the striatum determined by real-time quantitative polymerase chain reaction 
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or the negative control Scramble first normalized with RNU6B (∆Ct), and them compared to those 
obtained in control animals (∆∆Ct), arbitrarily assigned as 1.0 (100% expression). Bars represent mean 
± SEM regarding miRNA relative value. * P < 0.05. n = 5 per group. 
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biological systems, including embryonic development, cell maintenance, chemical signaling, and 
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3. iscussion
R interference (R i) is undoubtedly the most significant scientific discovery of the last
two decades and is being exploited in many drugs for clinical testing [9]. The first one to
complete the phase III will probably reach the pharmaceutical market this year, i.e., two decades
after the seminal article of Fire and Melo awarded by Nobel Prize in Physiology or Medicine
2006 “for their discovery of RNA interference—gene silencing by double-stranded RNA” (https://
www.nobelprize.org/nobel_prizes/medicine/laureates/2006/#) [19–21]. Following this outstanding
work, many initial reports about RNAi focused fundamentally on suppressing genes of interest by
using small-interfering RNAs (siRNAs) [22]. Our group has successfully silenced target genes by
using different knocking-down strategies (i.e., synthetic oligos or short-hairpin expression vectors),
working ith both in vitro and in vivo assays, in neurological and non-neurological models [23–27].
More recently, however, a new class of RNAi molecules entered the scenario for playing an even
more notorious role in science and technology: the microRNAs (miRNAs) [28,29]. miRNAs regulate
mRNA content at a post-transcriptional level for aiding many vital functions in different biological
systems, including embryonic development, cell aintenance, chemical signaling, and apoptosis,
as revised elsewhere [3,30]. On the other hand, miRNAs aberrantly expressed contribute to
underlying mechanisms of neurodegenerative diseases [31–33]. Controlling the content of pathological
miRNAs by synthetic oligonucleotides (inhibitors or mimics) is thus a promising therapeutic
strategy [4,34]. An illustrative example is miR-134, a microRNA implicated in health-disease processes
including excitatory neurotransmission, neuritogenesis, spinal growth, and neuroplasticity [35–39].
Overexpression of miR-134 occurs in areas of brain degeneration related to epileptogenesis, and the
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silencing of this miRNA by i.c.v. injection of antisense oligos prevented both the loss of brain cells and
the severity of the neurological process [5,6].
Since the early introduction of small-interfering molecules for RNAi-mediated gene silencing, two
major challenges came about: the first was to provide a sustained effect on the targeted genes—which
was achieved by chemical changes in RNA nucleotides [9,40]; the second was delivery [41,42].
The particle initially used was lipofectamine, a true liposome i.e., a lipid-vesicle capable of carrying
nucleic acids into its inner aqueous core [43]. Our group has employed lipofectamine for delivering
short-hairpin RNAi expression vectors and synthetic small-interfering RNAs (siRNAs) into astrocytic
brain tumor cells in culture [24–26]. This carrier was also helpful for delivering siRNAs, as reported in
dopaminergic neurons in vitro [27] and in a model of disk degeneration [23]. Lipid carriers evolved
drastically, and many new features have improved particle stability, lysosomal scape, and even
site-directed delivery particularly helpful for systemically-administered siRNAs now in advanced
phases of clinical testing [9]. Non-lipid carriers also became available, and the poly(lactic-co-glycolic
acid)—PLGA biodegradable polymeric particle is a representative example [44]. We reported that
PLGA provides sustained delivery of drugs in vivo [45]. This carrier also enabled a continuous
delivery of siRNAs (siGLODErs) when introduced into human tumoral tissues [9]. Finally, we have
also used the cationic polymeric particle INTERFERin® (Polyplus-transfection SA) for transfecting
antisense miRNA inhibitors into dopaminergic cells in culture, which provided neuroprotection against
rotenone-induced cell damage [8]. Our experience indicates that choosing the proper nanoparticle is a
critical step in preliminary planning and will affect the oligonucleotide efficacy directly.
Besides the significant technical advances of the aforementioned particles, developing carriers
capable of delivery oligonucleotides in the brain is still an unmet need. Neurons are hard to transfect,
and the blood–brain barrier represents an obstacle for delivering oligonucleotides into the central
nervous system [9]. Magnetofection technology emerged as an effective strategy to overcome such
limitations, allowing efficient delivery of functionally active oligonucleotides in vivo [46]. The present
study tested the magnetic particle NeuroMag® composed by polystyrene copolymers coated with iron,
developed for transfecting primary neurons, as well as neuronal and glial cell lines. Soto-Sánchez et al.
(2015) showed for the first time the capacity of this magnetoparticle to deliver nucleic acids in vivo [18].
NeuroMag®-complexed plasmids driven by a magnetic fields selectively transfected pyramidal cells
of the rat visual cortex. Our data corroborated this finding but using a distinct genetic structure (a
9 Kb double-stranded circular plasmid DNA versus a short single-stranded oligonucleotide used
here), as NeuroMag® efficiently delivered Antimir-134 to cortical neurons, avoiding other cell types
(Figure S1 of supplementary material). In both studies, the particle transfected nucleic acids into both
the soma and apical dendrites of pyramidal neurons. Furthermore, the characterization data for the
magnetic particles was consistent with our previous results [18]. The increase in average diameter of
magnetic particles and decrease in superficial charge after conjugation with miRNA oligos indicate
effective adsorption on the surface of Neuromag®. Changes in particle size may reflect the space filled
by oligonucleotides around the particle while the reduction in zeta potential an electrical change may
be caused by the negatively charged phosphate groups of nucleic acids [18,47].
Magnetofection with NeuroMag® also presented an improved feature after i.c.v. injection.
AntimiRs were efficiently biodistributed across the ependymal cell layer, reaching neurons and glial
cells in the rat striatum. This finding highlighted the use of i.c.v. route for promoting a more widespread
distribution of oligonucleotides in the striatum that is an anatomically extended brain structure in
rostrocaudal direction. In summary, microRNAs inhibitors (AntimiRs) complexed with NeuroMag®
are capable of decreasing the content of targeted miRNAs overexpressed in brain diseases including
PD, in which the striatal degeneration is a key pathological hallmark.
In the present study, in addition to the magnetofection strategy used to enhance the
oligonucleotides delivery, we also paid special attention to the AntimiR-134 chemical structure.
We intended to cause silencing effects specifically on miR-134 and remaining for at least seven days
after AntimiR-134 i.c.v. injection. These aims thus demanded a nucleotide molecule with increased
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specificity and stability. The oligos used our study were synthesized with two special modifications
for improving nuclease stability with reduced immunogenicity and off-target effects: (i) change in the
nucleotide ribose ring to make locked nucleic acids (LNA); and (ii) substitution of the phosphodiester
linkages between nucleotides by phosphorothioate ones [9,40]. Our group has reported that the same
AntimiR0s chemical changes employed in this study could produce an efficient down-regulation of a
specific microRNA in dopaminergic cells in culture [8]. Therefore, the cell-specific miRNA silencing
and the extended duration of knockdown are striking advantages for an RNAi-based therapeutics
exploitable for chronic neurodegenerative diseases.
In conclusion, this work found that Neuromag® is a valuable magnetic particle for delivering
AntimiRs in vivo, and that magnetofection of i.c.v. injected oligos can suppress target miRNAs
in striatum for at least 7 days. This RNAi-based therapeutic strategy could be of value for
regulating pathological miRNAs overexpressed in the striatum, a brain area critically relevant for
PD. The therapeutic potential of NeuroMag®-complexed miR-134 inhibitors in controlling underlying
mechanisms of PD could be examined in further studies with pre-clinical models of PD.
4. Materials and Methods
4.1. Animals and Surgical Procedures
Female adults Sprague–Dawley rats (250–300 g) were used in the assays (n = 5 per group).
The animals were housed in cages and kept in a room maintained at a controlled temperature of 23  C
and 55% humidity, with 12/12 h light-dark cycle. Throughout all the experiment period, food and
water were available ad libitum. All experimental techniques approved by the Committee for Ethics in
Animal Use of the University of Brasília, under UnBdoc No. 45524/2016.
4.2. Size and Zeta Potential Measurements
Particle size of magneto nanoparticle (Neuromag®, San Diego, CA, USA) and anti-miRNA
magnetoplexes vectors was determined by dynamic light scattering (DLS) and their superficial charge
by laser Doppler micro-electrophoresis. The measurements were taken on a Zetasizer Nano ZS
(Malvern Instruments, Malvern, UK). Samples were diluted in NaCl 0.1 mM Milli-Q water) and all
measurements were carried out in triplicate.
4.3. Surgical Procedures
We first carried out rat analgesia by using buprenorphine [0.025 mg kg 1 subcutaneous (s.c)].
Second, the anesthesia and sedation were induced by a cocktail of ketamine HCl (40 mg kg 1 i.p)
and diazepam [5 mg kg 1 intraperitoneal (i.p)]. Anesthesia was maintained with a mix of oxygen
and isofluorane (2%). During the procedure, the rats were monitored to: (a) depth of the anesthesia
by continuous evaluation of the heart rate and blinking and toe pinch reflexes; (b) record of the O2
concentration levels in the blood; and (c) maintenance of the animals0 bodies warmed by using a
thermal pad.
For intracerebroventricular (i.c.v.) injections of NeuroMag®-complexed oligonucleotides this work
used the following coordinates A: +0.7; L:  2.3; D:  5.2 from Bregma, according to the atlas of Paxinos
and Watson (2015) [48]. We drilled a small craniotomy to expose the dura mater and arachnoids of the
rat. Before the injection, fluorescein isothiocyanate (FITC)-labeled oligonucleotides (0.36 nmol in 0.36
µL; Exiqon A/S, Vedbaek, Denmark) were incubated with 0.68 µL of NeuroMag® (Magnetofection™,
OZ Biosciences USA Inc., San Diego, CA, USA) for at least 20 min at 37  C. After that, a Hamilton
33-gauge needle micro-syringe (Hamilton Company, Reno, NV, USA) was held within the stereotaxic
frame to inject in the right ventricle a total volume of 1 µL of the NeuroMag®-oligonucleotide solution
for 10 min. The needle remained in situ for an additional 10 min before being removed slowly. A
magnetic plate was placed underneath the head for 30 min to drive magnetic particles towards and
into the brain cells, according to previous work [18] (Sóto-Sanches et al., 2015). After the surgical
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procedure, the animals were housed in their cages for 7 days, in a temperature and light-controlled
room with a 12 h light/darkness cycle. A post-surgery treatment with antibiotics (enrofloxacin 25 mg
kg 1 s.c.), anti-inflammatory and analgesic drugs (meloxicam 2 mg kg 1 s.c.) were administered.
4.4. Tissue Processing
At Day 7 after the stereotaxic injection of Neuromag®-complexed oligos, rats were perfused
under general anesthesia through the left ventricle of the heart with phosphate buffered saline (PBS;
10–15 min), followed by 4% paraformaldehyde (PFA; 10–15 min). Brains were removed and submitted
to a 4% PFA for 48 h followed by sucrose gradient (10%, 20%, and 30%) in a shaker at room temperature.
Next, the coronal sections of the rat brain were cut (20 µm) in a freezing microtome (CM1850, Leica,
Wetzlar, Germany) throughout the rostrocaudal extent.
4.5. Immunohistochemistry of Nano-Structured Molecule in the Striatum
We first treated brain sections with 1 mM cupric sulfate (CuSO4) in 50 mM ammonium acetate
buffer for removing autofluorescence. Then, sections were incubated for 1 h in 10% normal bovine
serum (Jackson, West Grove, PA, USA) with 0.5% Triton X-100 for blocking unspecific staining. Next,
the samples were incubated overnight at room temperature with chicken anti-EGFP (Invitrogen,
1:100, Carlsbad, CA, USA) and rabbit anti-NeuN (Millipore, 1:300, Darmstadt, Germany) antibodies
diluted in PBS containing 0.5% Triton X-100. The sections were washed in PBS and incubated with
secondary antibodies, donkey anti-rabbit IgG (Alexa Fluor 633-conjugated; 1:100; Invitrogen) and
goat anti-chicken (IgG Alexa Fluor 555-conjugated; 1:100; Invitrogen, Carlsbad, CA, USA) for 1 h.
This study employed Hoechst 33342 reagent for labeling cells nuclei. Finally, the brain sections were
washed in PBS, mounted in fluoromount Vectashield (Vector Laboratories, Burlingame, CA, USA)
and coverslipped for analysis by laser-confocal microscopy (Leica TCS SPE Microsystems GmbH,
Wetzlar, Germany). Immunohistochemical controls were performed by omission of either the primary
or secondary antibodies (data not shown).
4.6. Quantification of Striatal miRNAs by Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR)
The striatum tissue was manually dissected from euthanized animals at Day 7 post-injection of
Neuromag®-complexed oligos, and frozen at  80  C. miRNAs were isolated by mirVana™ miRNA
Isolation Kit, and quantified by fluorometry (Qubit® 2.0 firmware 3.11; Thermo Fisher Scientific, Inc.,
Waltham, MA, USA). Following the cDNA synthesis (TaqMan MicroRNA Reverse Transcription kit,
Applied Biosystems; Thermo Fisher Scientific, Inc.), miR-134a was quantified by RT-qPCR using
the TaqMan system (QuantStudio 12K Flex system, Applied Biosystems; Thermo Fisher Scientific,
Inc.). The reaction mix contained 2 µL cDNA, 1 µL miRNA miR-134 specific primer or the internal
control RNU6B (both from Thermo Fisher Scientific, Inc.), 10 µL TaqMan® Fast Advanced Master
Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) and milli-Q pure water to 20 µL. The qPCR
program consisted of two initial cycles (50  C for 2min, 95  C for 20 s), with posterior 40 amplification
cycles (95  C for 1min, 60  C for 1 min). Each run was executed in triplicate, and included negative
RT (non-template) controls. Relative expression of microRNAs was determined by the delta delta CT
method (2 DDCt) [49].
4.7. Statistical Analysis
Results were analyzed by using SPSS software (Statistical Package for Social Sciences 17.0; SPSS,
Inc., Chicago, IL, USA). Student0s t-test was used to evaluate differences between paired groups.
P < 0.05 was considered statistically significant.
Supplementary Materials: The following is available online, Figure S1: Magnetofection of Neuromag®-complexed
FITC-labeled oligos in cortical cells.
Molecules 2018, 23, 1825 9 of 11
Author Contributions: R.T.d.A. and E.F. conceived and designed the experiments; S.S.T.d.A., C.H.H., and C.S.-S.
performed the experiments.
Funding: The present study received financial support from CAPES [Coordenação de Aperfeiçoamento de Pessoal
de Nível Superior (Programa Nacional de Pós-doutorado; grant no. 3731-37/2010)], CNPq [Conselho Nacional de
Desenvolvimento Científico e Tecnológico (grant no. 467467/2014-5)] and FAP-DF [Fundação de Apoio à Pesquisa
do Distrito Federal (grant no. 2010/00302-9)].
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509–524. [CrossRef]
[PubMed]
2. Hebert, S.S.; De Strooper, B. Alterations of the microRNA network cause neurodegenerative disease.
Trends Neurosci. 2009, 32, 199–206. [CrossRef] [PubMed]
3. Carthew, R.W.; Sontheimer, E.J. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009, 136, 642–655.
[CrossRef] [PubMed]
4. Henshall, D.C. Antagomirs and microRNA in status epilepticus. Epilepsia 2013, 54, 17–19. [CrossRef]
[PubMed]
5. Jimenez-Mateos, E.M.; Engel, T.; Merino-Serrais, P.; McKiernan, R.C.; Tanaka, K.; Mouri, G.; Sano, T.;
O’Tuathaigh, C.; Waddington, J.L.; Prenter, S.; et al. Silencing microRNA-134 produces neuroprotective and
prolonged seizure-suppressive effects. Nat. Med. 2012, 18, 1087–1094. [CrossRef] [PubMed]
6. Jimenez-Mateos, E.M.; Engel, T.; Merino-Serrais, P.; Fernaud-Espinosa, I.; Rodriguez-Alvarez, N.; Reynolds, J.;
Reschke, C.R.; Conroy, R.M.; McKiernan, R.C.; de Felipe, J.; et al. Antagomirs targeting microRNA-134
increase hippocampal pyramidal neuron spine volume in vivo and protect against pilocarpine-induced
status epilepticus. Brain Struct. Funct. 2015, 220, 2387–2399. [CrossRef] [PubMed]
7. Reschke, C.R.; Silva, L.F.; Norwood, B.A.; Senthilkumar, K.; Morris, G.; Sanz-Rodriguez, A.; Conroy, R.M.;
Costard, L.; Neubert, V.; Bauer, S.; et al. Potent Anti-seizure Effects of Locked Nucleic Acid Antagomirs
Targeting miR-134 in Multiple Mouse and Rat Models of Epilepsy. Mol. Ther. Nucl. Acids 2017, 6, 45–56.
[CrossRef] [PubMed]
8. Horst, C.H.; Titze-de-Almeida, R.; Titze-de-Almeida, S.S. The involvement of Eag1 potassium channels and
miR-34a in rotenone-induced death of dopaminergic SH-SY5Y cells. Mol. Med. Rep. 2017, 15, 1479–1488.
[CrossRef] [PubMed]
9. Titze-de-Almeida, R.; David, C.; Titze-de-Almeida, S.S. The Race of 10 Synthetic RNAi-Based Drugs to the
Pharmaceutical Market. Pharm. Res. 2017, 34, 1339–1363. [CrossRef] [PubMed]
10. Yin, H.; Kanasty, R.L.; Eltoukhy, A.A.; Vegas, A.J.; Dorkin, J.R.; Anderson, D.G. Non-viral vectors for
gene-based therapy. Nat. Rev. Genet. 2014, 15, 541–555. [CrossRef] [PubMed]
11. Mintzer, M.A.; Simanek, E.E. Nonviral vectors for gene delivery. Chem. Rev. 2009, 109, 259–302. [CrossRef]
[PubMed]
12. Zhao, C.; Strappe, P.M.; Lever, A.M.; Franklin, R.J. Lentiviral vectors for gene delivery to normal and
demyelinated white matter. Glia 2003, 42, 59–67. [CrossRef] [PubMed]
13. Jin, L.; Zeng, X.; Liu, M.; Deng, Y.; He, N. Current progress in gene delivery technology based on chemical
methods and nano-carriers. Theranostics 2014, 4, 240–255. [CrossRef] [PubMed]
14. Pezzoli, D.; Chiesa, R.; De Nardo, L.; Candiani, G. We still have a long way to go to effectively deliver genes!
J. Appl Biomater. Funct. Mater. 2012, 10, 82–91. [CrossRef] [PubMed]
15. Pickard, M.R.; Chari, D.M. Robust uptake of magnetic nanoparticles (MNPs) by central nervous system
(CNS) microglia: Implications for particle uptake in mixed neural cell populations. Int. J. Mol. Sci. 2010, 11,
967–981. [CrossRef] [PubMed]
16. Plank, C.; Zelphati, O.; Mykhaylyk, O. Magnetically enhanced nucleic acid delivery. Ten years of
magnetofection-progress and prospects. Adv. Drug Deliv. Rev. 2011, 63, 1300–1331. [CrossRef] [PubMed]
17. Yiu, H.H. Engineering the multifunctional surface on magnetic nanoparticles for targeted biomedical
applications: A chemical approach. Nanomedicine 2011, 6, 1429–1446. [CrossRef] [PubMed]
Molecules 2018, 23, 1825 10 of 11
18. Soto-Sanchez, C.; Martinez-Navarrete, G.; Humphreys, L.; Puras, G.; Zarate, J.; Pedraz, J.L.; Fernandez, E.
Enduring high-efficiency in vivo transfection of neurons with non-viral magnetoparticles in the rat visual
cortex for optogenetic applications. Nanomedicine 2015, 11, 835–843. [CrossRef] [PubMed]
19. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic
interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391, 806–811. [CrossRef]
[PubMed]
20. Morrison, C. Alnylam prepares to land first RNAi drug approval. Nat. Rev. Drug Discov. 2018, 17, 156–157.
[CrossRef] [PubMed]
21. Nghiem, S. Market watch: Upcoming market catalysts in Q3 2017. Nat. Rev. Drug Discov. 2017, 16, 449.
[CrossRef] [PubMed]
22. Shan, G. RNA interference as a gene knockdown technique. Int. J. Biochem. Cell Biol. 2010, 42, 1243–1251.
[CrossRef] [PubMed]
23. Castania, V.; Issy, A.C.; Silveira, J.W.; Ferreira, F.R.; Titze-de-Almeida, S.S.; Resende, F.F.; Ferreira, N.R.;
Titze-de-Almeida, R.; Defino, H.L.; Del Bel, E. The Presence of the Neuronal Nitric Oxide Synthase Isoform
in the Intervertebral Disk. Neurotox. Res. 2017, 31, 148–161. [CrossRef] [PubMed]
24. Cunha, L.C.; Del Bel, E.; Pardo, L.; Stuhmer, W.; Titze, D.E.A.R. RNA interference with EAG1 enhances
interferon gamma injury to glioma cells in vitro. Anticancer Res. 2013, 33, 865–870. [PubMed]
25. Resende, F.F.B.; Titze-de-Almeida, S.S.; Titze-de-Almeida, R. Function of neuronal nitric oxide synthase
enzyme in temozolomide-induced damage of astrocytic tumor cells. Oncol. Lett. 2018, 15, 4891–4899.
[CrossRef] [PubMed]
26. Sales, T.T.; Resende, F.F.; Chaves, N.L.; Titze-De-Almeida, S.S.; Bao, S.N.; Brettas, M.L.; Titze-De-Almeida, R.
Suppression of the Eag1 potassium channel sensitizes glioblastoma cells to injury caused by temozolomide.
Oncol. Lett. 2016, 12, 2581–2589. [CrossRef] [PubMed]
27. Titze-de-Almeida, S.S.; Lustosa, C.F.; Horst, C.H.; Bel, E.D.; Titze-de-Almeida, R. Interferon Gamma
potentiates the injury caused by MPP(+) on SH-SY5Y cells, which is attenuated by the nitric oxide synthases
inhibition. Neurochem. Res. 2014, 39, 2452–2464. [CrossRef] [PubMed]
28. Pillai, R.S. MicroRNA function: Multiple mechanisms for a tiny RNA? RNA 2005, 11, 1753–1761. [CrossRef]
[PubMed]
29. Wahid, F.; Shehzad, A.; Khan, T.; Kim, Y.Y. MicroRNAs: Synthesis, mechanism, function, and recent clinical
trials. Biochim. Biophys. Acta 2010, 1803, 1231–1243. [CrossRef] [PubMed]
30. Bushati, N.; Cohen, S.M. microRNA functions. Annu. Rev. Cell Dev. Biol. 2007, 23, 175–205. [CrossRef]
[PubMed]
31. Gascon, E.; Gao, F.B. Cause or Effect: Misregulation of microRNA Pathways in Neurodegeneration.
Front. Neurosci. 2012, 6, 48. [CrossRef] [PubMed]
32. Junn, E.; Mouradian, M.M. MicroRNAs in neurodegenerative diseases and their therapeutic potential.
Pharm. Ther. 2012, 133, 142–150. [CrossRef] [PubMed]
33. Martino, S.; di Girolamo, I.; Orlacchio, A.; Datti, A.; Orlacchio, A. MicroRNA implications across
neurodevelopment and neuropathology. J. Biomed. Biotechnol. 2009, 2009, 654346. [CrossRef] [PubMed]
34. Titze-de-Almeida, R.; Titze-de-Almeida, S.S. miR-7 replacement therapy in Parkinson’s disease.
Curr. Gene Ther. 2018. [CrossRef] [PubMed]
35. Coolen, M.; Bally-Cuif, L. MicroRNAs in brain development and physiology. Curr. Opin. Neurobiol. 2009, 19,
461–470. [CrossRef] [PubMed]
36. Henshall, D.C. MicroRNA and epilepsy: Profiling, functions and potential clinical applications.
Curr. Opin. Neurol. 2014, 27, 199–205. [CrossRef] [PubMed]
37. Meng, Y.; Zhang, Y.; Tregoubov, V.; Janus, C.; Cruz, L.; Jackson, M.; Lu, W.Y.; MacDonald, J.F.; Wang, J.Y.;
Falls, D.L.; et al. Abnormal spine morphology and enhanced LTP in LIMK-1 knockout mice. Neuron 2002, 35,
121–133. [CrossRef]
38. Numakawa, T.; Richards, M.; Adachi, N.; Kishi, S.; Kunugi, H.; Hashido, K. MicroRNA function and
neurotrophin BDNF. Neurochem. Int. 2011, 59, 551–558. [CrossRef] [PubMed]
39. Schratt, G.M.; Tuebing, F.; Nigh, E.A.; Kane, C.G.; Sabatini, M.E.; Kiebler, M.; Greenberg, M.E. A brain-specific
microRNA regulates dendritic spine development. Nature 2006, 439, 283–289. [CrossRef] [PubMed]
40. Kanasty, R.; Dorkin, J.R.; Vegas, A.; Anderson, D. Delivery materials for siRNA therapeutics. Nat. Mater.
2013, 12, 967–977. [CrossRef] [PubMed]
Molecules 2018, 23, 1825 11 of 11
41. Kim, D.H.; Rossi, J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 2007, 8,
173–184. [CrossRef] [PubMed]
42. Whitehead, K.A.; Langer, R.; Anderson, D.G. Knocking down barriers: Advances in siRNA delivery. Nat. Rev.
Drug Discov. 2009, 8, 129–138. [CrossRef] [PubMed]
43. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4,
145–160. [CrossRef] [PubMed]
44. Singha, K.; Namgung, R.; Kim, W.J. Polymers in small-interfering RNA delivery. Nucl. Acid Ther. 2011, 21,
133–147. [CrossRef] [PubMed]
45. Amaral, A.C.; Bocca, A.L.; Ribeiro, A.M.; Nunes, J.; Peixoto, D.L.; Simioni, A.R.; Primo, F.L.; Lacava, Z.G.;
Bentes, R.; Titze-de-Almeida, R.; et al. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and
dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis. J. Antimicrob. Chemother.
2009, 63, 526–533. [CrossRef] [PubMed]
46. Krotz, F.; de Wit, C.; Sohn, H.Y.; Zahler, S.; Gloe, T.; Pohl, U.; Plank, C. Magnetofection—A highly efficient
tool for antisense oligonucleotide delivery in vitro and in vivo. Mol. Ther. 2003, 7, 700–710. [CrossRef]
47. Puras, G.; Mashal, M.; Zarate, J.; Agirre, M.; Ojeda, E.; Grijalvo, S.; Eritja, R.; Diaz-Tahoces, A.;
Martinez Navarrete, G.; Aviles-Trigueros, M.; et al. A novel cationic niosome formulation for gene delivery
to the retina. J. Control. Release 2014, 174, 27–36. [CrossRef] [PubMed]
48. Paxinos, G.; Watson, C. The Rat Brain in Stereotaxic Coordinates, 5th ed.; Elsevier Academic Press: San Diego,
CA, USA, 2005.
49. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are not available from the authors.
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
